ABT’s Freestyle Libre continuous glucose monitor, which has annualized sales of ~$5B (#msg-171723150) and is expected to reach $10B by 2028 (#msg-170908065), makes ABT a bona fide T2D investment play.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”